From: Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials
Study | Age (years) | Duration of diabetes (years) | BMI (kg/m2) | Hypertension (n,%) | SBP (mmHg) | DBP (mmHg) |
---|---|---|---|---|---|---|
A Ahmann 2015 | I:59.3(9.2) | I:12.1(7.1) | I:32.3(5.6) | Unavailable | Unavailable | Unavailable |
P:57.5(11.1) | P:12.1(6.8) | P:32.2(5.7) | ||||
A Astrup 2009 | I:47.2(9.7)†| NA | I:34.8(2.6)†| Unavailable | I:127(13.1)†| I:79.7(9.1)†|
45.5(10.9)‡ | 35.0(2.6)‡ | 123(13.0)‡ | 77.9(7.9)‡ | |||
45.0(11.1)§ | 35.0(2.8)§ | 126(13.9)§ | 78.6(8.2)§ | |||
45.9(10.7)â™ | 34.8(2.8)â™ | 124(11.3)â™ | 77.8(8.3)â™ | |||
P:45.9(10.3) | P:34.9(2.8) | P:124(11.1) | P:76.8(8.5) | |||
A Astrup 2012 | I:47.2(9.7)†| NA | I:34.8(2.6)†| Unavailable | I:127(13.1)†| I:79.7(9.1)†|
45.5(10.9)‡ | 35.0(2.6)‡ | 123(13.0)‡ | 77.9(7.9)‡ | |||
45.0(11.1)§ | 35.0(2.8)§ | 126(13.9)§ | 78.6(8.2)§ | |||
45.9(10.7)â™ | 34.8(2.8)â™ | 124(11.3)â™ | 77.8(8.3)â™ | |||
P:45.9(10.3) | P:34.9(2.8) | P:124(11.1) | P:76.8(8.5) | |||
A Blackman 2016 | I:48.6 (9.9) | NA | I:38.9(6.4) | I:75,41.7% | I:125.8(11.5) | I:81.2(7.6) |
P:48.4(9.5) | P:39.4(7.4) | P:77,43% | P:127.1(12.3) | P:82.2(8.8) | ||
Christian 2015 | I:39.5(2.7) | I:18.33(2.0) | I:24.17(0.64) | Unavailable | I:129.4(2.5) | I:75.5(1.7) |
P:36.1(1.6) | P:19.56(1.6) | P:22.75(0.41) | P:127.3(2.2) | P:72.5(1.4) | ||
Dejgaard 2016 | I:47(13) | I:20(12) | I:30.3(3.5) | Unavailable | I:131(15) | I:82(9) |
P:49(12) | P:25(12) | P:29.8(3.1) | P:130(16) | P:81(8) | ||
LEAD-1 | I:57.7(9)†| I:6.7(4.0,10.7)*†| I:29.8(5.1)†| I:155,68%†| I:133(15)†| Unavailable |
55.6(10)‡ | 6.5(3.7,10.5)*‡ | 30.0(5.1)‡ | 163,69.7%‡ | 132(16)‡ | ||
P:54.7(10) | P:6.5(4.5,10.6)* | P:30.3(5.4) | P:74,64.9% | P:131(15.3) | ||
LEAD-2 | I:57.0(9)†| I:7.0(5)†| I:31.1(4.8)†| Unavailable | I:132(14)†| I:80(10)†|
57.0(9)‡ | 8.0(5)‡ | 30.9(4.6)‡ | 131(14)‡ | 79(8)‡ | ||
P:56.0(9) | P:8.0(6) | P:31.6(4.4) | P:135(16) | P:81(9) | ||
LEAD-4 | I:55.0(10)†| I:9.0(6)†| I:33.2(5.4)†| Unavailable | I:129(14.8)†| I:75.8(9.0)†|
55.0(11)‡ | 9.0(6)‡ | 33.5(5.1)‡ | 126(14.2)‡ | 75.2(8.4)‡ | ||
P:55.0(10) | P:9.0(6) | P:33.9(5.2) | P:128(14.5) | P:76.2(9.2) | ||
LEAD-5 | I:57.6(9.5) | I:9.2(5.8) | I:30.4(5.3) | Unavailable | I:135(15.0) | I:80.8(9.1) |
P:57.5(9.6) | P:9.4(6.2) | P:31.3(5.0) | P:133(14.0) | P:80.4(9.3) | ||
LEADERS trial | I:64.2(7.2) | I:12.8(8.0) | I:32.5(6.3) | Unavailable | I:135.9(17.8) | I:77.2(10.3) |
P:64.4(7.2) | P:12.9(8.1) | P:32.5(6.3) | P:135.9(17.7) | P:77.0(10.1) | ||
Mark M. Smits 2016 | I:62.8(6.9) | Unavailable | I:32.0(30.9–35.9)* | Unavailable | I:136.6(17.0) | I:77.0(5.4) |
P:137.6(14.9) | P:76.4(6.8) | |||||
P:62.8(6.9) | ||||||
P:30.8(28.9–31.5)* | ||||||
MDI liraglutide trial | I:63.7(8.2) | I:17.3(7.6) | I:33.7(4.3) | Unavailable | I:137.9(16.8) | I:73.5(12.7) |
P:63.5(7.7) | P:17.0(8.1) | P:33.5(4.0) | P:133.7(13.7) | P:74.9(8.5) | ||
Nandy 2014 | I:57.7(9) | I:5.3(4.1) | I:32.7(4.5) | Unavailable | Unavailable | Unavailable |
P:60.3(7.3) | P:8.4(4.6) | P:31.6(4.2) | ||||
P. Mensberg MSc 2016 | I:56.5(9) | I:6(5.2) | I:32.5(3.7) | Unavailable | I:136.4(11.0) | I:84.1(7.0) |
P:55.6(12) | P:3.7(3.3) | P:32.4(5.2) | P:136.2(8.9) | P:82.1(7.0) | ||
Robert 2015 | I:34(9) | NA | I:36.15(3.84) | 0,0% | I:130(15) | I:76(11) |
P:34(9) | P:35.74(4.55) | P:133(17) | P:78(10) | |||
S Frossing 2018 | I:29.9(6.1) | NA | I:33.3(5.1) | 0,0% | I:123(9) | I:79(8) |
P:29.9(6.1) | P:33.3(4.6) | P:124(9) | P:80(7) | |||
Sun H. Kim 2013 | I:58.0(7) | NA | I:31.9(2.7) | 0,0% | I:127(10) | I:76(9) |
P:58.0(8) | P:31.9(3.5) | P:119(14) | P:75(8) |